MedTrace Logo

Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)

NCT00084799 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-10-04

Study results available
· View outcomes & findings →

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with progressive small cell lung cancer (SCLC).

Conditions

Interventions

BIOLOGICAL

monoclonal antibody hu3S193

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Ludwig Institute for Cancer Research

    lead OTHER

Principal Investigators

  • Lee M. Krug, MD · Memorial Sloan Kettering Cancer Center

  • Chaitanya R. Divgi, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-26
Primary Completion
2006-01-25
Completion
2006-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00084799 on ClinicalTrials.gov